XML 71 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' equity (Details)
1 Months Ended 12 Months Ended
Mar. 11, 2024
USD ($)
$ / shares
shares
Feb. 10, 2023
Sep. 02, 2022
USD ($)
Feb. 28, 2023
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
Vote
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Nov. 08, 2024
USD ($)
Jan. 26, 2024
USD ($)
Nov. 12, 2020
USD ($)
Common stock                  
Stock, shares authorized | shares         440,000,000 440,000,000      
Common stock, shares authorized | shares         400,000,000 400,000,000      
Common stock, par value (in dollars per share) | $ / shares         $ 0.001 $ 0.001      
Preferred stock, shares authorized | shares         40,000,000 40,000,000      
Preferred stock, par value (in dollars per share) | $ / shares         $ 0.001 $ 0.001      
Common stock issuable upon conversion (in shares) | shares         28,112        
Reverse stock split ratio   0.05              
Number of voting rights per common share | Vote         1        
Shelf Registration Statement                  
Maximum amount to be issued under universal shelf registration statement                 $ 350,000,000
Proceeds from issuance of common stock         $ 16,140,356 $ 5,788,918      
Common stock issuance costs         1,318,461 $ 648,928      
Pre-funded Warrants                  
March 2024 Private Placement                  
Warrant exercises         $ 0        
Series A Convertible Preferred Stock                  
Common stock                  
Convertible preferred stock, shares outstanding | shares         56,227 56,227      
Number of shares remained to be converted into common stock | shares         56,227        
March 2024 Private Placement | Pre-funded Warrants                  
March 2024 Private Placement                  
Warrants to purchase of shares | shares         507,076        
March 2024 Private Placement | Purchasers | Securities purchase agreement                  
Shelf Registration Statement                  
Shares issued | shares 1,687,712                
Issue price per share | $ / shares $ 7.29                
Common stock issuance costs $ 1,300,000                
March 2024 Private Placement                  
Common stock with an exercise price | $ / shares $ 0.001                
Percentage of outstanding shares 4.99%                
Proceeds from sale of common stock in a private placement $ 16,000,000                
Expected gross proceeds from potential future warrants cash exercise $ 18,000,000                
March 2024 Private Placement | Purchasers | Securities purchase agreement | At the election of holder                  
March 2024 Private Placement                  
Percentage of outstanding shares 9.99%                
March 2024 Private Placement | Purchasers | Securities purchase agreement | Pre-funded Warrants                  
March 2024 Private Placement                  
Offering price per share | $ / shares $ 7.289                
Warrants to purchase of shares | shares 507,076                
March 2024 Private Placement | Purchasers | Securities purchase agreement | Tranche A Warrants (Pre-funded Warrants Exercise Price 7.29 Per Share)                  
March 2024 Private Placement                  
Warrants to purchase of shares | shares 1,097,394                
Common stock with an exercise price | $ / shares $ 7.29                
Stock issuance anniversary period 3 years                
Number of days after announcement of Phase 2 dose for ATRN-119 30 days                
Volume weighted average price | $ / shares $ 14.58                
Number of consecutive trading days 30 days                
March 2024 Private Placement | Purchasers | Securities purchase agreement | Tranche B Warrants (Pre-funded Warrants Exercise Price 9.1125 Per Share)                  
March 2024 Private Placement                  
Warrants to purchase of shares | shares 1,097,394                
Common stock with an exercise price | $ / shares $ 9.1125                
Stock issuance anniversary period 5 years                
Number of days after announcement of Phase 2 dose for ATRN-119 30 days                
Volume weighted average price | $ / shares $ 18.225                
Number of consecutive trading days 30 days                
2020 Shelf Registration Statement                  
Shelf Registration Statement                  
Shares issued | shares       1,050,000          
Issue price per share | $ / shares       $ 5.25          
Proceeds from issuance of common stock       $ 4,900,000          
Common stock issuance costs       $ 600,000          
ATM offering                  
Common stock                  
Number of shares issued | shares           26,302      
Commission payable as a percentage of gross proceeds from sale of common stock under ATM offering     3.00%            
Shelf Registration Statement                  
Maximum amount to be issued under at-the-market offering program     $ 14,744,728            
Proceeds from issuance of common stock           $ 300,000      
Common stock issuance costs           $ 8,000      
2024 Shelf Registration Statement                  
Shelf Registration Statement                  
Maximum amount to be issued under universal shelf registration statement               $ 150,000,000  
Maximum amount to be issued under at-the-market offering program               1,000,000  
Maximum amount to be issued under at-the-market offering program, supplement             $ 3,000,000 2,000,000  
2024 Shelf Registration Statement | HCW                  
Shelf Registration Statement                  
Maximum amount to be issued under at-the-market offering program             $ 3,000,000    
2024 ATM offering                  
Shelf Registration Statement                  
Shares issued | shares         41,152        
Proceeds from issuance of common stock         $ 100,000        
Common stock issuance costs         $ 6,000        
2024 ATM offering | HCW                  
Shelf Registration Statement                  
Maximum amount to be issued under at-the-market offering program               $ 2,000,000